In what could be a notice to the incoming Donald Trump administration and any reform ideas it may have, the US FDA has reiterated its long-held wisdom that randomized, controlled Phase III clinical trials (RCTs) should remain the gold standard to meet the risk/benefit threshold for approval.
A report released Jan. 19, the eve of inauguration day, notes that although advances in science have allowed...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?